Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma

References

• Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002; 9:387-99; PMID:12410178
   PubMedGoogle Scholar
• Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15:1179; PMID:15277256; http://dx.doi.org/10.1093/annonc/mdh308
   PubMed Web of Science ®Google Scholar
• Brockstein BE. Management of recurrent head and neck cancer: recent progress and future directions. Drugs 2011; 71:1551-9; PMID:21861540; http://dx.doi.org/10.2165/11592540-000000000-00000
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10:257-63; PMID:1732427
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Mitch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol. 1992; 10:1241-51; PMID:1634913
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23:8646-54; PMID:16314626; http://dx.doi.org/10.1200/JCO.2005.02.4646
   PubMed Web of Science ®Google Scholar
• Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24:2644-52; PMID:16763278; http://dx.doi.org/10.1200/JCO.2005.05.3348
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010; 21:252-61; PMID:20943624; http://dx.doi.org/10.1093/annonc/mdq453
   PubMed Web of Science ®Google Scholar
• Price KA, Cohen EE. Current Treatment Options for Metastatic Head and Neck Cancer. Curr Treat Options Oncol 2012; 13:35-46; PMID:22252884; http://dx.doi.org/10.1007/s11864-011-0176-y
   PubMed Web of Science ®Google Scholar
• Asaumi J, Nishijima K. Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer. In Vivo 1996; 10:559-62; PMID:8986464
   PubMed Web of Science ®Google Scholar
• Browman GP, Archibald SD, Young JE, Hryniuk WM, Russell R, Kiehl K, Levine MN. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1983; 1:787-92; PMID:6366132
   PubMed Web of Science ®Google Scholar
• Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. U Clin Oncol 2006; 24:2666; PMID:16763281; http://dx.doi.org/10.1200/JCO.2005.04.8306
   PubMed Web of Science ®Google Scholar
• Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58:959-65; PMID:14967456; http://dx.doi.org/10.1016/j.ijrobp.2003.07.010
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Clin Oncol 2006; 24:4170-6; PMID:16943533; http://dx.doi.org/10.1200/JCO.2006.07.2587
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-7; PMID:12743152; http://dx.doi.org/10.1200/JCO.2003.10.051
   PubMed Web of Science ®Google Scholar
• Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:8418-842; PMID:16322304; http://dx.doi.org/10.1158/1078-0432.CCR-05-1247
   PubMed Web of Science ®Google Scholar
• Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006; 94:631-6; PMID:16495923
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-71; PMID:19289630; http://dx.doi.org/10.1200/JCO.2008.17.0530
   PubMed Web of Science ®Google Scholar
• Airoldi M, Pedani F, Brando V, Gabriele P, Orecchia R. Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity. Chemioterapia 1987; 6:390-2; PMID:3435920
   PubMedGoogle Scholar
• Tortochaux J, Tao Y, Tournay E, Lapeyre M, Lesaunier F, Bardet E, Janot F, Lusinchi A, Benhamou E, Bontemps P, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol 2011; 100:70-5; PMID:21741720; http://dx.doi.org/10.1016/j.radonc.2011.06.025
   PubMed Web of Science ®Google Scholar
• Schornagel JH, Verweij J, de Mulder PH, Lapeyre M, Lesaunier F, Bardet E, Janot F, Lusinchi A, Benhamou E, Bontemps P, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 1995; 13:1649-55; PMID:7602354
   PubMed Web of Science ®Google Scholar
• Pitman SW, Kowal CD, Bertino JR. Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer. Semin Oncol 1983; 10:15-9; PMID:6346497
   PubMed Web of Science ®Google Scholar
• Ringborg U, Ewert G, Kinnman J, Lundqvist PG, Strander H. Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck. Cancer 1983; 52:971-3; PMID:6603896; http://dx.doi.org/10.1002/1097-0142(19830915)52: 6<971::AID-CNCR2820520606>3.0.CO;2-B
   PubMedGoogle Scholar
• Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009; 9:1421-8; PMID:19828002; http://dx.doi.org/10.1586/era.09.113
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570-9; PMID:8445433
   PubMed Web of Science ®Google Scholar
• Shiraki M, Odajima T, Ikeda T, Sasaki A, Satoh M, Yamaguchi A, Noguchi M, Nagai I, Hiratsuka H. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol 2005; 18:1482-9; PMID:16007067; http://dx.doi.org/10.1038/modpathol.3800455
   PubMed Web of Science ®Google Scholar